Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients.

ABSTRACT:

Background

Denosumab is widely used to prevent skeletal-related events (SREs) in patients with bone metastases. However, rebound bone resorption after discontinuation is recognized. In osteoporosis, discontinuation of low-dose denosumab increases multiple vertebral fractures, but data on high-dose discontinuation remain limited.

Methods

Among 493 patients treated with high-dose denosumab at our institution (2014-2023), 78 met eligibility criteria. SREs during and after treatment were compared using each patient as their own control. SREs were defined as pathological fracture, spinal cord compression, or radiotherapy/surgery for metastatic bone pain. Hypercalcemia, benign fragility fractures, and serum ALP level were also assessed.

Results

A total of 11 SREs were obser

SUBMITTER: Setsu N 

PROVIDER: S-EPMC12547457 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature